Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival

Breast Cancer Research and Treatment

Volumn 110, Issue 3, 2008, Pages 531-539

  Toi, Masakazu ^a   Nakamura, Seigo ^b   Kuroi, Katsumasa ^c   Iwata, Hiroji ^d   Ohno, Shinji ^e   Masuda, Norikazu ^f   Kusama, Mikihiro ^g   Yamazaki, Kosuke ^h   Hisamatsu, Kazuhumi ⁱ   Sato, Yasuyuki ^j   Kashiwaba, Masahiro ^k   Kaise, Hiroshi ^l   Kurosumi, Masafumi ^m   Tsuda, Hitoshi ⁿ   Akiyama, Futoshi ^o   Ohashi, Yasuo ^p   Takatsuka, Yuichi ^q  

^a KYOTO UNIVERSITY   (Japan)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f OSAKA NATIONAL HOSPITAL   (Japan)

^g Sinjyuku Breast Center Kusama Clinic   (Japan)

^h Sapporo Kotoni Breast Clinic   (Japan)

ⁱ HIROSHIMA CITY ASA HOSPITAL   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^k IWATE MEDICAL UNIVERSITY   (Japan)

^l TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^m SAITAMA CANCER CENTER   (Japan)

ⁿ NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^o CANCER INSTITUTE   (Japan)

^p UNIVERSITY OF TOKYO   (Japan)

^q KANSAI ROSAI HOSPITAL   (Japan)

more..

Author keywords

Clinical trial; Docetaxel; Early stage breast cancer; FEC; Phase II; Preoperative chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL;

ADULT; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; JAPAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MASTECTOMY; MENTAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHOTOTOXICITY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CELL; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; PREOPERATIVE CARE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS; TREATMENT OUTCOME;

EID: 46949111665     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9744-z     Document Type: Article

References (37)

1. Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469
2. Kaufmann M, Hortobagyi GN, Goldhirsch A et al (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940-1949
3. Bear HD, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-27. J Clin Oncol 21:4165-4174
4. Chang JC, Wooten EC, Tsimelzon A et al (2005) Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23:1169-1177
5. Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493
6. Smith IC, Heys SD, Hutcheon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466
7. Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027
8. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313
9. Roché H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 trial. J Clin Oncol 24:5664-5671
10. Estévez LG, Gradishar WJ (2004) Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 10:3249-3261
11. Nowak AK, Wilcken NR, Stockler MR et al (2004) Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 5:372-380
12. Berry DA, Cirrincione C, Henderson IC et al (2004) Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-year experience of the CALGB & U.S. Breast Intergroup. Breast Cancer Res Treat 88:S17 (Abstr 29)
13. Kuroi K, Toi M, Tsuda H et al (2006) Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer 13:38-48
14. Kurosumi M (2004) Significance of histopathological evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 11:139-147
15. Merchant WJ, Millis RR, Smith P et al (1999) Expression of c-erbB2 and p53 protein is similar in breast cancer from British and Japanese women. Int J Cancer 84:278-283
16. von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685
17. von Minckwitz G, Blohmer JU, Raab G et al (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann Oncol 16:56-63
18. Cramer E, Moers C, Zarghooni V et al (2006) Neoadjuvant, biweekly, dose-dense chemotherapy with epirubicin (E) and cyclophosphamide (C) followed by docetaxel (T) in primary breast cancer (BC). Proc Am Soc Clin Oncol 24 (Abstr 10656)
19. Joensuu H, Kellokumpu-Lehtinen P, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast Cancer. N Engl J Med 354:809-820
20. Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-102
21. Di Leo A, Chan S, Paesmans M et al (2004) HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 86:197-206
22. Cummings J, Smyth JF (1993) DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 4:533-543
23. Di Leo A, Isola J (2003) Topoisomerase IIalpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer 4:179-186
24. Tanner M, Isola J, Wiklund T et al (2006) Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. Scandinavian Breast Group Trial 9401. J Clin Oncol 24:2409-2411
25. Di Leo A, Larsimont D, Gancberg D et al (2001) HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 12:1081-1089
26. Buzdar AU (2006) Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. J Clin Oncol 24(16): 2428-2436
27. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol 21:1431-1439
28. Mamounas EP, Bryant J, Lembersky B et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686-3696
29. Berry DA, Cirrincione C, Henderson IC et al (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667
30. Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from the escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983
31. Colleoni M, Viale G, Zahrieh D et al (2004) Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10:6622-6628
32. Morrow M, Krontiras H (2001) Who should not receive chemotherapy? Data from American databases and trials. J Natl Cancer Inst Monogr 30:109-113
33. Norton L (2001) Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6(suppl 3):30-35
34. Tsuruo T, Naito M, Tomida A et al (2003) Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94:15-21
35. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297-309
36. Toi M, Rahman MA, Bando H, Chow LW (2005) Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 6:158-166
37. Dressler LG, Berry DA, Broadwater G et al (2005) Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23:4287-4297